Advertisement
Canada markets close in 5 hours 22 minutes

  • S&P/TSX

    21,883.24
    +89.34 (+0.41%)
     

  • S&P 500

    5,485.85
    +7.95 (+0.15%)
     

  • DOW

    39,223.75
    +95.95 (+0.25%)
     

  • CAD/USD

    0.7309
    +0.0010 (+0.14%)
     

  • CRUDE OIL

    81.62
    +0.72 (+0.89%)
     

  • Bitcoin CAD

    84,793.46
    +384.73 (+0.46%)
     

  • CMC Crypto 200

    1,294.76
    +28.62 (+2.26%)
     

  • GOLD FUTURES

    2,335.00
    +21.80 (+0.94%)
     

  • RUSSELL 2000

    2,025.57
    +7.45 (+0.37%)
     

  • 10-Yr Bond

    4.2850
    -0.0310 (-0.72%)
     

  • NASDAQ

    17,850.44
    +45.28 (+0.25%)
     

  • VOLATILITY

    12.40
    -0.15 (-1.20%)
     

  • FTSE

    8,213.63
    -11.70 (-0.14%)
     

  • NIKKEI 225

    39,341.54
    -325.53 (-0.82%)
     

  • CAD/EUR

    0.6818
    -0.0013 (-0.19%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB BUT MICRON SLIDES, WITH DATA IN FOCUS

U.S. economic growth for last quarter revised up slightly to 1.4% annual rate

Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Alector, Inc.
·1 min read
Alector, Inc.
Alector, Inc.

SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5th Annual Neuro Perspectives Conference, being held virtually on Thursday, June 27, 2024.

A webcast of the presentation will be available on the “Events & Presentations” page at 7:00 a.m. ET within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.

About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

ADVERTISEMENT

Alector Contacts:

Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com

1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com

Argot Partners (investors)
Laura Perry
212.600.1902
alector@argotpartners.com